These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 10821989)

  • 21. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
    Moatti JP; Carrieri MP; Spire B; Gastaut JA; Cassuto JP; Moreau J
    AIDS; 2000 Jan; 14(2):151-5. PubMed ID: 10708285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
    Reynaud-Maurupt C; Carrieri MP; Gastaud JA; Pradier C; Obadia Y; Moatti JP
    AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug treatment as HIV prevention: expanding treatment options.
    Metzger DS; Zhang Y
    Curr HIV/AIDS Rep; 2010 Nov; 7(4):220-5. PubMed ID: 20803321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
    Carrieri MP; Vlahov D; Dellamonica P; Gallais H; Lepeu G; Spire B; Obadia Y
    Drug Alcohol Depend; 2000 Jul; 60(1):51-4. PubMed ID: 10821989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.
    Wolfe D; Carrieri MP; Shepard D
    Lancet; 2010 Jul; 376(9738):355-66. PubMed ID: 20650513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
    Spire B; Lucas GM; Carrieri MP
    Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV treatment as prevention among injection drug users.
    Wood E; Milloy MJ; Montaner JS
    Curr Opin HIV AIDS; 2012 Mar; 7(2):151-6. PubMed ID: 22227587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine use: the international experience.
    Carrieri MP; Amass L; Lucas GM; Vlahov D; Wodak A; Woody GE
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S197-215. PubMed ID: 17109307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.